Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers
Clin Transl Oncol. 2021 Apr 19. doi: 10.1007/s12094-021-02613-w. Online ahead of print.ABSTRACTThe year 2019 witnessed the first approval of an immune checkpoint inhibitor (ICI) for the management of triple negative breast cancers (TNBC) that are metastatic and programmed death ligand (PD)-L1 positive. Extensive research has focused on testing ICI-based combinatorial strategies, with the ultimate goal of enhancing the response of breast tumors to immunotherapy to increase the number of breast cancer patients benefiting from this transformative treatment. The promising investigational strategies included immunotherapy combi...
Source: Clinical Breast Cancer - April 19, 2021 Category: Cancer & Oncology Authors: M F Tolba H Elghazaly E Bousoik M M A Elmazar S M Tolaney Source Type: research

Precision oncology in metastatic colorectal cancer - from biology to medicine
Nat Rev Clin Oncol. 2021 Apr 16. doi: 10.1038/s41571-021-00495-z. Online ahead of print.ABSTRACTRemarkable progress has been made in the development of biomarker-driven targeted therapies for patients with multiple cancer types, including melanoma, breast and lung tumours, although precision oncology for patients with colorectal cancer (CRC) continues to lag behind. Nonetheless, the availability of patient-derived CRC models coupled with in vitro and in vivo pharmacological and functional analyses over the past decade has finally led to advances in the field. Gene-specific alterations are not the only determinants that can...
Source: Clinical Breast Cancer - April 17, 2021 Category: Cancer & Oncology Authors: Federica Di Nicolantonio Pietro Paolo Vitiello Silvia Marsoni Salvatore Siena Josep Tabernero Livio Trusolino Rene Bernards Alberto Bardelli Source Type: research

The Prognostic Value of Lymph Node Metastasis and the Eighth Edition of AJCC for Patients with Anaplastic Thyroid Cancer
CONCLUSIONS: This study demonstrated that LNM was independently associated with poor prognosis of ATC, and AJCC-v8 with the modified staging of patients with LNM showed better survival predictive performance in ATC patients than AJCC-v7.PMID:33864292 | DOI:10.1111/cen.14482 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 17, 2021 Category: Cancer & Oncology Authors: Hanpu Zhang Yan-Ci Zhao Qi Wu Lijun Wang Shengrong Sun Source Type: research

Precision oncology in metastatic colorectal cancer - from biology to medicine
Nat Rev Clin Oncol. 2021 Apr 16. doi: 10.1038/s41571-021-00495-z. Online ahead of print.ABSTRACTRemarkable progress has been made in the development of biomarker-driven targeted therapies for patients with multiple cancer types, including melanoma, breast and lung tumours, although precision oncology for patients with colorectal cancer (CRC) continues to lag behind. Nonetheless, the availability of patient-derived CRC models coupled with in vitro and in vivo pharmacological and functional analyses over the past decade has finally led to advances in the field. Gene-specific alterations are not the only determinants that can...
Source: Clinical Breast Cancer - April 17, 2021 Category: Cancer & Oncology Authors: Federica Di Nicolantonio Pietro Paolo Vitiello Silvia Marsoni Salvatore Siena Josep Tabernero Livio Trusolino Rene Bernards Alberto Bardelli Source Type: research

The Prognostic Value of Lymph Node Metastasis and the Eighth Edition of AJCC for Patients with Anaplastic Thyroid Cancer
CONCLUSIONS: This study demonstrated that LNM was independently associated with poor prognosis of ATC, and AJCC-v8 with the modified staging of patients with LNM showed better survival predictive performance in ATC patients than AJCC-v7.PMID:33864292 | DOI:10.1111/cen.14482 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 17, 2021 Category: Cancer & Oncology Authors: Hanpu Zhang Yan-Ci Zhao Qi Wu Lijun Wang Shengrong Sun Source Type: research

Precision oncology in metastatic colorectal cancer - from biology to medicine
Nat Rev Clin Oncol. 2021 Apr 16. doi: 10.1038/s41571-021-00495-z. Online ahead of print.ABSTRACTRemarkable progress has been made in the development of biomarker-driven targeted therapies for patients with multiple cancer types, including melanoma, breast and lung tumours, although precision oncology for patients with colorectal cancer (CRC) continues to lag behind. Nonetheless, the availability of patient-derived CRC models coupled with in vitro and in vivo pharmacological and functional analyses over the past decade has finally led to advances in the field. Gene-specific alterations are not the only determinants that can...
Source: Clinical Breast Cancer - April 17, 2021 Category: Cancer & Oncology Authors: Federica Di Nicolantonio Pietro Paolo Vitiello Silvia Marsoni Salvatore Siena Josep Tabernero Livio Trusolino Rene Bernards Alberto Bardelli Source Type: research

The Prognostic Value of Lymph Node Metastasis and the Eighth Edition of AJCC for Patients with Anaplastic Thyroid Cancer
CONCLUSIONS: This study demonstrated that LNM was independently associated with poor prognosis of ATC, and AJCC-v8 with the modified staging of patients with LNM showed better survival predictive performance in ATC patients than AJCC-v7.PMID:33864292 | DOI:10.1111/cen.14482 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 17, 2021 Category: Cancer & Oncology Authors: Hanpu Zhang Yan-Ci Zhao Qi Wu Lijun Wang Shengrong Sun Source Type: research

Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia
CONCLUSION: Similar efficacy was demonstrated for eribulin when given in the first-line to beyond the fifth line of chemotherapy in all subtypes of MBC.PMID:33855786 | DOI:10.1111/ajco.13576 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 15, 2021 Category: Cancer & Oncology Authors: Arlene Chan Christopher Lomma HuiJun Chih Elizabeth Blackely Natasha Woodward Daphne Tsoi Kerry Cheong Mitchell Chipman Andrew Redfern Source Type: research

TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis
J Clin Invest. 2021 Apr 15;131(8):139434. doi: 10.1172/JCI139434.ABSTRACTImmune checkpoint blockade therapy has demonstrated promising clinical outcomes for multiple cancer types. However, the emergence of resistance as well as inadequate biomarkers for patient stratification have largely limited the clinical benefits. Here, we showed that tumors with high TYRO3 expression exhibited anti-programmed cell death protein 1/programmed death ligand 1 (anti-PD-1/PD-L1) resistance in a syngeneic mouse model and in patients who received anti-PD-1/PD-L1 therapy. Mechanistically, TYRO3 inhibited tumor cell ferroptosis triggered by an...
Source: Clinical Breast Cancer - April 15, 2021 Category: Cancer & Oncology Authors: Zhou Jiang Seung-Oe Lim Meisi Yan Jennifer L Hsu Jun Yao Yongkun Wei Shih-Shin Chang Hirohito Yamaguchi Heng-Huan Lee Baozhen Ke Jung-Mao Hsu Li-Chuan Chan Gabriel N Hortobagyi Liuqing Yang Chunru Lin Dihua Yu Mien-Chie Hung Source Type: research

Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia
CONCLUSION: Similar efficacy was demonstrated for eribulin when given in the first-line to beyond the fifth line of chemotherapy in all subtypes of MBC.PMID:33855786 | DOI:10.1111/ajco.13576 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 15, 2021 Category: Cancer & Oncology Authors: Arlene Chan Christopher Lomma HuiJun Chih Elizabeth Blackely Natasha Woodward Daphne Tsoi Kerry Cheong Mitchell Chipman Andrew Redfern Source Type: research

TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis
J Clin Invest. 2021 Apr 15;131(8):139434. doi: 10.1172/JCI139434.ABSTRACTImmune checkpoint blockade therapy has demonstrated promising clinical outcomes for multiple cancer types. However, the emergence of resistance as well as inadequate biomarkers for patient stratification have largely limited the clinical benefits. Here, we showed that tumors with high TYRO3 expression exhibited anti-programmed cell death protein 1/programmed death ligand 1 (anti-PD-1/PD-L1) resistance in a syngeneic mouse model and in patients who received anti-PD-1/PD-L1 therapy. Mechanistically, TYRO3 inhibited tumor cell ferroptosis triggered by an...
Source: Clinical Breast Cancer - April 15, 2021 Category: Cancer & Oncology Authors: Zhou Jiang Seung-Oe Lim Meisi Yan Jennifer L Hsu Jun Yao Yongkun Wei Shih-Shin Chang Hirohito Yamaguchi Heng-Huan Lee Baozhen Ke Jung-Mao Hsu Li-Chuan Chan Gabriel N Hortobagyi Liuqing Yang Chunru Lin Dihua Yu Mien-Chie Hung Source Type: research

Spiritual based intervention effect on the psychological aspect of patients with gynaecologic and breast cancer: A systematic review
Enferm Clin. 2021 Apr;31 Suppl 2:S90-S95. doi: 10.1016/j.enfcli.2020.09.006.ABSTRACTThe complexity of care on patients with gynaecological and breast cancer causes various psychological effects, and therefore, spiritual-based intervention is developed to overcome these problems. The purpose of this study is to determine the effects of the spiritual-based intervention on the psychological aspect of patients with gynaecological and breast cancer. The method used to prepare this systematic review is Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). There are 14 related articles. Spiritual-based inte...
Source: Clinical Breast Cancer - April 14, 2021 Category: Cancer & Oncology Authors: Lina Anisa Nasution Yati Afiyanti Source Type: research

Counterpoint: Does Mastectomy Reduce Overall Survival in Early Stage Breast Cancer?
Clin Oncol (R Coll Radiol). 2021 Apr 10:S0936-6555(21)00105-9. doi: 10.1016/j.clon.2021.03.014. Online ahead of print.NO ABSTRACTPMID:33849779 | DOI:10.1016/j.clon.2021.03.014 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 14, 2021 Category: Cancer & Oncology Authors: D Dodwell D Wheatley Source Type: research

Characteristics and clinical outcome of pT1a-b node-negative breast cancer
CONCLUSION: The results of the study provided that both T1a and T1b tumors have a good and similar prognosis.PMID:33851075 | PMC:PMC8039097 | DOI:10.14744/nci.2020.06332 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 14, 2021 Category: Cancer & Oncology Authors: Abdilkerim Oyman Mustafa Basak Hatice Odabas Melike Ozcelik Source Type: research

Spiritual based intervention effect on the psychological aspect of patients with gynaecologic and breast cancer: A systematic review
Enferm Clin. 2021 Apr;31 Suppl 2:S90-S95. doi: 10.1016/j.enfcli.2020.09.006.ABSTRACTThe complexity of care on patients with gynaecological and breast cancer causes various psychological effects, and therefore, spiritual-based intervention is developed to overcome these problems. The purpose of this study is to determine the effects of the spiritual-based intervention on the psychological aspect of patients with gynaecological and breast cancer. The method used to prepare this systematic review is Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). There are 14 related articles. Spiritual-based inte...
Source: Clinical Breast Cancer - April 14, 2021 Category: Cancer & Oncology Authors: Lina Anisa Nasution Yati Afiyanti Source Type: research

Counterpoint: Does Mastectomy Reduce Overall Survival in Early Stage Breast Cancer?
Clin Oncol (R Coll Radiol). 2021 Apr 10:S0936-6555(21)00105-9. doi: 10.1016/j.clon.2021.03.014. Online ahead of print.NO ABSTRACTPMID:33849779 | DOI:10.1016/j.clon.2021.03.014 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 14, 2021 Category: Cancer & Oncology Authors: D Dodwell D Wheatley Source Type: research

Characteristics and clinical outcome of pT1a-b node-negative breast cancer
CONCLUSION: The results of the study provided that both T1a and T1b tumors have a good and similar prognosis.PMID:33851075 | PMC:PMC8039097 | DOI:10.14744/nci.2020.06332 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 14, 2021 Category: Cancer & Oncology Authors: Abdilkerim Oyman Mustafa Basak Hatice Odabas Melike Ozcelik Source Type: research

Competing-Risk Nomograms for Predicting the Prognosis of Patients With Infiltrating Lobular Carcinoma of the Breast
CONCLUSION: We applied competing-risk analysis to ILC patients based on the SEER database and established nomograms that perform well in predicting the cause-specific death rates at 3, 5, and 10 years after the diagnosis.PMID:33846097 | DOI:10.1016/j.clbc.2021.03.008 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 13, 2021 Category: Cancer & Oncology Authors: Fengshuo Xu Chengzhuo Li Xiang Li Qiao Huang Didi Han Hui Wang Shuai Zheng Jun Lyu Source Type: research

Diagnostic Performance of Adjunctive Imaging Modalities Compared to Mammography Alone in Women with Non-Dense and Dense Breasts: A Systematic Review and Meta-Analysis
Clin Breast Cancer. 2021 Mar 16:S1526-8209(21)00061-6. doi: 10.1016/j.clbc.2021.03.006. Online ahead of print.ABSTRACTPURPOSE: To compare the diagnostic performance of mammography (MG) alone versus MG combined with adjunctive imaging modalities, including handheld ultrasound (HHUS), automated breast ultrasound (ABUS), digital breast tomosynthesis (DBT), contrast-enhanced mammography (CEM), and magnetic resonance imaging (MRI) in women with non-dense and dense breasts.PATIENTS AND METHODS: Medline, Embase, PubMed, CINAHL, Scopus, and the Web of Science databases were searched up to October 2019. Quality assessment was perfo...
Source: Clinical Breast Cancer - April 13, 2021 Category: Cancer & Oncology Authors: Ibrahim Hadadi William Rae Jillian Clarke Mark McEntee Ernest Ekpo Source Type: research

Long-term Survival Comparison of Repeated Breast-conserving Surgery Versus Mastectomy for Patients with DCIS with Ipsilateral Breast Tumor Recurrence: A Real-world Longitudinal Study
CONCLUSION: We suggest that repeated BCS with radiation therapy deserves consideration when DCIS survivors suffered IBTR. The choice of surgical management should be tailored based on patients' age at IBTR diagnosis and size of recurrent disease.PMID:33846099 | DOI:10.1016/j.clbc.2021.02.012 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 13, 2021 Category: Cancer & Oncology Authors: Qing Li Kang Wang Ling Yang Qianxue Wu Wenming Zhu Zhuyue Li Yang Shi Xiang Zhang Hongyuan Li Source Type: research

An insight into the promoter methylation of PHF20L1 and the gene association with metastasis in breast cancer
CONCLUSIONS: Our findings showed differences in methylation of PHF20L1 promoter region near TSS and upstream in BC subtypes; its overexpression impacted DMFS. We found that PHF20L1 is targeted by miR96-5p, miR9-5p and miR182-5p, which are involved in proliferation and metastasis, and regulates genes engaged in processes such as alternative splicing.PMID:33847474 | DOI:10.17219/acem/133426 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 13, 2021 Category: Cancer & Oncology Authors: Jose Alfredo Sierra-Ramirez Emmanuel Sese ña-Mendez Marycarmen Godinez-Victoria Marta Elena Hernandez-Caballero Source Type: research

Myeloid cell-derived PROS1 inhibits tumor metastasis by regulating inflammatory and immune responses via IL-10
J Clin Invest. 2021 Apr 13:126089. doi: 10.1172/JCI126089. Online ahead of print.ABSTRACTStimulation of TAM (TYRO3, AXL and MERTK) Receptor Tyrosine Kinases promotes tumor progression through numerous cellular mechanisms. TAM cognate ligands GAS6 and PROS1 (for TYRO3 and MERTK) are secreted by host immune cells, an interaction which may support tumor progression. Here we reveal an unexpected anti-metastatic role for myeloid-derived PROS1, directly suppressing the metastatic potential of lung and breast tumor models. Pros1 deletion in myeloid cells led to increased lung metastasis, independent of primary tumor infiltration....
Source: Clinical Breast Cancer - April 13, 2021 Category: Cancer & Oncology Authors: Avi Maimon Victor Levi-Yahid Kerem Ben-Meir Amit Halpern Ziv Talmi Shivam Priya Gabriel Mizraji Shani Mistriel-Zerbib Michael Berger Michal Baniyash Sonja Loges Tal Burstyn-Cohen Source Type: research

Competing-Risk Nomograms for Predicting the Prognosis of Patients With Infiltrating Lobular Carcinoma of the Breast
CONCLUSION: We applied competing-risk analysis to ILC patients based on the SEER database and established nomograms that perform well in predicting the cause-specific death rates at 3, 5, and 10 years after the diagnosis.PMID:33846097 | DOI:10.1016/j.clbc.2021.03.008 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 13, 2021 Category: Cancer & Oncology Authors: Fengshuo Xu Chengzhuo Li Xiang Li Qiao Huang Didi Han Hui Wang Shuai Zheng Jun Lyu Source Type: research

Diagnostic Performance of Adjunctive Imaging Modalities Compared to Mammography Alone in Women with Non-Dense and Dense Breasts: A Systematic Review and Meta-Analysis
Clin Breast Cancer. 2021 Mar 16:S1526-8209(21)00061-6. doi: 10.1016/j.clbc.2021.03.006. Online ahead of print.ABSTRACTPURPOSE: To compare the diagnostic performance of mammography (MG) alone versus MG combined with adjunctive imaging modalities, including handheld ultrasound (HHUS), automated breast ultrasound (ABUS), digital breast tomosynthesis (DBT), contrast-enhanced mammography (CEM), and magnetic resonance imaging (MRI) in women with non-dense and dense breasts.PATIENTS AND METHODS: Medline, Embase, PubMed, CINAHL, Scopus, and the Web of Science databases were searched up to October 2019. Quality assessment was perfo...
Source: Clinical Breast Cancer - April 13, 2021 Category: Cancer & Oncology Authors: Ibrahim Hadadi William Rae Jillian Clarke Mark McEntee Ernest Ekpo Source Type: research

Long-term Survival Comparison of Repeated Breast-conserving Surgery Versus Mastectomy for Patients with DCIS with Ipsilateral Breast Tumor Recurrence: A Real-world Longitudinal Study
CONCLUSION: We suggest that repeated BCS with radiation therapy deserves consideration when DCIS survivors suffered IBTR. The choice of surgical management should be tailored based on patients' age at IBTR diagnosis and size of recurrent disease.PMID:33846099 | DOI:10.1016/j.clbc.2021.02.012 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 13, 2021 Category: Cancer & Oncology Authors: Qing Li Kang Wang Ling Yang Qianxue Wu Wenming Zhu Zhuyue Li Yang Shi Xiang Zhang Hongyuan Li Source Type: research

Thermal Ablation as an Alternative for Surgical Resection of Small ( 2 cm) Breast Cancers: A Meta-Analysis
Clin Breast Cancer. 2021 Mar 17:S1526-8209(21)00059-8. doi: 10.1016/j.clbc.2021.03.004. Online ahead of print.ABSTRACTWomen with early-stage breast cancer have an excellent prognosis with current therapy, but could presumably be treated less invasively, without the need for surgery. The primary goal of this meta-analysis was to examine whether thermal ablation is an effective method to treat early-stage breast cancer. Studies reporting on complete ablation rate after thermal ablation as a treatment of small breast cancers (≤ 2 cm) were included. Methodologic quality of included studies was assessed using MINORS criteria...
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Elles M F van de Voort Gerson M Struik Erwin Birnie Adriaan Moelker Cornelis Verhoef Taco M A L Klem Source Type: research

Clinical management among individuals with variant of uncertain significance in hereditary cancer: A systematic review and meta-analysis
Clin Genet. 2021 Apr 12. doi: 10.1111/cge.13966. Online ahead of print.ABSTRACTImproper medical use of variant of uncertain significance (VUS) remains a concern in hereditary cancer genetic testing. The goal of this study was to assess the association between pathogenic and likely pathogenic (P/LP), VUS, and benign and likely benign (B/LB) genetic test results and cancer-related surgical and screening management. Systematic searches of Medline, Embase, EBSCO CINAHL Plus, and PsycINFO were conducted from 1946 to August 26, 2020. Eligible studies included individuals with cancer genetic test result and surgical or screening ...
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Sukh Makhnoon Erica M Bednar Kate J Krause Susan K Peterson Maria A Lopez-Olivo Source Type: research

Neratinib: an option for HER2-positive metastatic breast cancer
Clin Adv Hematol Oncol. 2020 Sep;18 Suppl 15(9):1-20.ABSTRACTMetastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer is currently incurable. The primary goals of treatment are to prolong survival while optimizing quality of life. Several agents are now available in this setting, including neratinib, tucatinib, ado-trastuzumab emtansine, and trastuzumab deruxtecan. Neratinib in combination with capecitabine was recently approved for the treatment of adult patients with advanced or metastatic breast cancer who have received 2 or more prior anti-HER2-based regimens in the metastatic setting. Neratini...
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Joyce A O'Shaughnessy Ruth O'Regan Claudine Isaacs Source Type: research

Treatment goals in the management of HER2-positive metastatic breast cancer
Clin Adv Hematol Oncol. 2020 Sep;18 Suppl 15(9):3-6.NO ABSTRACTPMID:33843839 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Ruth O'Regan Source Type: research

Neratinib: clinical trial data in HER2-positive metastatic breast cancer
Clin Adv Hematol Oncol. 2020 Sep;18 Suppl 15(9):7-11.NO ABSTRACTPMID:33843840 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Joyce A O'Shaughnessy Source Type: research

Incorporating neratinib into clinical practice for patients with HER2-positive metastatic breast cancer
Clin Adv Hematol Oncol. 2020 Sep;18 Suppl 15(9):12-15.NO ABSTRACTPMID:33843841 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Claudine Isaacs Source Type: research

Neratinib: an option for HER2-positive metastatic breast cancer--Q & amp;A
Clin Adv Hematol Oncol. 2020 Sep;18 Suppl 15(9):15-17.NO ABSTRACTPMID:33843842 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Joyce A O'Shaughnessy Ruth O'Regan Claudine Isaacs Source Type: research

Neratinib in the early-stage/extended adjuvant breast cancer patient
Clin Adv Hematol Oncol. 2020 Aug;18 Suppl 12(8):1-20.ABSTRACTBreast cancer is the most common tumor type observed in women in the United States. The majority of patients are diagnosed at an early stage, but the disease often recurs after initial treatment. Human epidermal growth factor receptor 2 (HER2) gene amplification is present in approximately 20% to 25% of breast tumors and is associated with invasive disease and an aggressive phenotype. The addition of anti-HER2 therapy to chemotherapy has significantly improved the prognosis for patients with these aggressive tumors. However, despite the dramatic advances in survi...
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Joyce A O'Shaughnessy Claudine Isaacs Ruth O'Regan Source Type: research

Risk of recurrence in early-stage, HER2-positive breast cancer
Clin Adv Hematol Oncol. 2020 Aug;18 Suppl 12(8):3-6.NO ABSTRACTPMID:33843844 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Claudine Isaacs Source Type: research

Neratinib in early-stage breast cancer: clinical trial data
Clin Adv Hematol Oncol. 2020 Aug;18 Suppl 12(8):7-10.NO ABSTRACTPMID:33843845 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Ruth O'Regan Source Type: research

Best use of neratinib in patients with early-stage breast cancer
Clin Adv Hematol Oncol. 2020 Aug;18 Suppl 12(8):11-16.NO ABSTRACTPMID:33843846 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Joyce A O'Shaughnessy Source Type: research

Neratinib in the early-stage/extended adjuvant breast cancer patient: Q & amp;A
Clin Adv Hematol Oncol. 2020 Aug;18 Suppl 12(8):16-17.NO ABSTRACTPMID:33843847 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Joyce A O'Shaughnessy Ruth O'Regan Claudine Isaacs Source Type: research

Highlights in metastatic breast cancer from the 2020 San Antonio Breast Cancer Symposium
Clin Adv Hematol Oncol. 2021 Jan;19 Suppl 1(1):1-20.NO ABSTRACTPMID:33843911 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Source Type: research

Highlights in metastatic breast cancer from the 2020 San Antonio Breast Cancer Symposium: commentary
Clin Adv Hematol Oncol. 2021 Jan;19 Suppl 1(1):18-19.NO ABSTRACTPMID:33843912 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Hope S Rugo Source Type: research

Highlights in early and metastatic breast cancer from the 2020 San Antonio Breast Cancer Symposium
Clin Adv Hematol Oncol. 2021 Feb;19 Suppl 9(2):1-24.NO ABSTRACTPMID:33843923 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Source Type: research

Highlights in early and metastatic breast cancer from the 2020 San Antonio Breast Cancer Symposium: commentary
Clin Adv Hematol Oncol. 2021 Feb;19 Suppl 9(2):18-23.NO ABSTRACTPMID:33843924 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Joyce A O'Shaughnessy Source Type: research

Highlights in metastatic breast cancer from the European Society for Medical Oncology Virtual Congress 2020
Clin Adv Hematol Oncol. 2020 Nov;18 Suppl 17(11):1-24.NO ABSTRACTPMID:33843925 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Source Type: research

Highlights in metastatic breast cancer from the European Society for Medical Oncology Virtual Congress 2020: commentary
Clin Adv Hematol Oncol. 2020 Nov;18 Suppl 17(11):20-23.NO ABSTRACTPMID:33843926 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Aditya Bardia Source Type: research

Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
CONCLUSION: Pembrolizumab monotherapy has antitumor activity in heavily pretreated patients with mBC characterized by HTMB. Our findings support the recent US Food and Drug Administration approval of pembrolizumab for treatment of patients with unresectable or metastatic solid tumors with HTMB without alternative treatment options.PMID:33844595 | DOI:10.1200/JCO.20.02923 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Ajjai S Alva Pam K Mangat Elizabeth Garrett-Mayer Susan Halabi Damien Hansra Carmen J Calfa Maged F Khalil Eugene R Ahn Timothy L Cannon Pamela Crilley Julie G Fisher Derrick S Haslem Sagun Shrestha Kaitlyn R Antonelli Nicole L Butler Sasha L Warren Andre Source Type: research

Traditional Korean medicine treatment for tamoxifen associated adverse events of breast cancer patient: A CARE - Compliant case report
CONCLUSION: This case report suggests that traditional Korean medicine interventions might have improved the adverse events of tamoxifen in breast cancer patients.PMID:33845285 | DOI:10.1016/j.ctcp.2021.101378 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Jihye Seo Donghun Lee Hee-Geun Jo Source Type: research

Does Mastectomy Reduce Overall Survival in Early Stage Breast Cancer?
Clin Oncol (R Coll Radiol). 2021 Apr 7:S0936-6555(21)00096-0. doi: 10.1016/j.clon.2021.03.005. Online ahead of print.NO ABSTRACTPMID:33838987 | DOI:10.1016/j.clon.2021.03.005 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 11, 2021 Category: Cancer & Oncology Authors: J Murphy A Gandhi Source Type: research

Locoregional Management of the Axilla in Mastectomy Patients with One or Two Positive Sentinel Nodes: The Role of Intraoperative Pathology
Clin Breast Cancer. 2021 Mar 13:S1526-8209(21)00054-9. doi: 10.1016/j.clbc.2021.02.013. Online ahead of print.ABSTRACTINTRODUCTION: Controversy exists regarding optimal management of the axilla in clinically node-negative (cN0) mastectomy patients with one or two positive sentinel lymph nodes (+SLNs). We evaluated the influence of frozen-section pathology on axillary management and recurrence.PATIENTS AND METHODS: We studied cN0 breast cancer patients treated from 2008 to 2018 with mastectomy and SLN surgery with one or two +SLNs. Patients with one or two +SLNs identified on frozen-section intraoperatively (FS+SLN) were co...
Source: Clinical Breast Cancer - April 11, 2021 Category: Cancer & Oncology Authors: John Davis Judy C Boughey Tanya L Hoskin Courtney N Day John C Cheville Mara A Piltin Tina J Hieken Source Type: research

Surface-guided radiation therapy for breast cancer: more precise positioning
CONCLUSIONS: SGRT improves patient positioning accuracy compared to skin markers. Optimal breast SGRT can accurately verify the localisation of the tumour bed, ensuring matching with ≥ 3 surgical clips. SGRT can eliminate unwanted radiation from IGRT verification systems.PMID:33840013 | DOI:10.1007/s12094-021-02617-6 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 11, 2021 Category: Cancer & Oncology Authors: A Gonz ález-Sanchis L Brualla-Gonz ález C Fuster-Diana J C Gordo-Partearroyo T Pi ñeiro-Vidal T Garc ía-Hernandez J L L ópez-Torrecilla Source Type: research

Social support, coping strategies and sociodemographic factors in women with breast cancer
CONCLUSION: Young people, a high level of education, having a partner, low psychological distress, and seeking social support were associated with the use of adaptive cancer coping strategies.PMID:33840046 | DOI:10.1007/s12094-021-02592-y (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 11, 2021 Category: Cancer & Oncology Authors: C Calderon D Gomez A Carmona-Bayonas R Hernandez I Ghanem M Gil Raga L Ostios Garcia M Garcia Carrasco M H Lopez de Ceballos E Ferreira P Jimenez-Fonseca Source Type: research

The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type
This study aimed to investigate the impact of receiving treatment at academic centers on the overall survival (OS) of cancer patients with brain metastases (BMs) regardless of the primary cancer site.METHODS: This retrospective analysis of the National Cancer Database (NCDB) included patients diagnosed with non-small cell lung cancer, small-cell lung cancer, other types of lung cancer, breast cancer, melanoma, colorectal cancer, and kidney cancer and had brain metastases at the time of diagnosis. The data were extracted from the de-identified file of the NCDB, a joint program of the Commission on Cancer of the American Col...
Source: Clinical Breast Cancer - April 10, 2021 Category: Cancer & Oncology Authors: Saber Amin Michael Baine Jane Meza Chi Lin Source Type: research